Gefitinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III or Stage IV Head and Neck Cancer
Stage III Squamous Cell Carcinoma of the Hypopharynx
Stage III Squamous Cell Carcinoma of the Larynx
Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity
Stage III Squamous Cell Carcinoma of the Oropharynx
Stage IV Squamous Cell Carcinoma of the Hypopharynx
Stage IV Squamous Cell Carcinoma of the Larynx
Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity
Stage IV Squamous Cell Carcinoma of the Oropharynx
Radiation: radiation therapy
Other: laboratory biomarker analysis
|Study Design:||Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A Phase I Study Of ZD 1839 In Combination With Radiation And Chemotherapy In Locally Advanced Squamous Cell Carcinoma Of The Head And Neck|
- Incidence of grade 4 or greater mucositis as scored by the National Cancer Institute (NCI) Common Toxicity Criteria v2.0 [ Time Frame: Up to 2 years ]Descriptive statistics (mean, median, range, standard deviation [s.d.], percentage, as appropriate) will be obtained.
- Incidence of grade 4 or greater skin toxicity as scored by the NCI Common Toxicity Criteria v2.0 [ Time Frame: Up to 2 years ]Descriptive statistics (mean, median, range, s.d., percentage, as appropriate) will be obtained.
- Incidence of any other grade 4 or greater toxicity as scored by the NCI Common Toxicity Criteria v2.0 [ Time Frame: Up to 2 years ]Descriptive statistics (mean, median, range, s.d., percentage, as appropriate) will be obtained.
- Primary tumor response rate as assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) [ Time Frame: 8 weeks ]Estimated with its 95% confidence interval.
- Response rates as assessed by the RECIST [ Time Frame: Up to 5 years ]Estimated with its 95% confidence interval.
- Relapse-free survival rates [ Time Frame: Up to 5 years ]
- Overall survival rates [ Time Frame: Up to 5 years ]Estimated using Kaplan-Meier curves.
- Biological effects of gefitinib within the primary tumor and skin [ Time Frame: Baseline ]Examined using linear or nonlinear mixed models. Reductions of labeling scores that are of prognostic importance will be determined by relating labeling scores to survival scores by statistical methods such as the Cox proportional hazards regression model.
|Study Start Date:||February 2002|
|Primary Completion Date:||April 2010 (Final data collection date for primary outcome measure)|
Experimental: Treatment (gefitinib, radiation therapy, cisplatin)
See detailed description.
Other Names:Radiation: radiation therapy
Undergo radiation therapy
Other Names:Drug: cisplatin
Other Names:Other: laboratory biomarker analysis
Hide Detailed Description
I. To establish the safety profile of daily oral administration of ZD1839 ("Iressa", AstraZeneca, Inc.) that can be given with concurrent irradiation alone or combined concurrently with weekly cisplatin in previously untreated patients with locally advanced HNSCC, AJCC clinical stage III-IVB, deemed not suitable for surgery. Hence, the maximum-tolerated dose of ZD1839 will be determined.
II. To delineate and quantitate any dose-dependent local and or systemic toxicities of ZD1839 given concurrently with irradiation or combined concurrently with weekly cisplatin to patients with locally advanced, HNSCC, AJCC stage III-IVB, deemed not suitable for surgery.
III. To determine the feasibility and toxicity profile of protracted continuous daily dosing of ZD1839 beginning 8 weeks after the completion of the head and neck radiation therapy for a period not to exceed 2 years.
I. Secondary endpoints will include determination of the response rates, relapse-free survival rates and overall survival rates for this group of patients.
II. To perform correlative studies assessing the biological effects of ZD1839 within the primary tumor.
OUTLINE: This is a multicenter, dose-escalation study of gefitinib.
All patients receive oral gefitinib once daily beginning at least 7 days before and continuing throughout radiotherapy or chemoradiotherapy in the absence of disease progression or unacceptable toxicity. Patients are entered into 1 of 5 levels.
Level I: Patients undergo concurrent boost radiotherapy 5 days per week comprising once daily radiotherapy for 3.5 weeks followed by twice daily radiotherapy for 2.5 weeks.
Level II: Patients receive escalated dose of gefitinib and undergo radiotherapy as in level I.
Level III: Patients receive original dose of gefitinib, undergo standard fractionation radiotherapy comprising once daily radiotherapy 5 days per week for 7 weeks, and receive cisplatin IV over 30-60 minutes at the beginning of each week of radiotherapy.
Level IV: Patients receive escalated dose of gefitinib as in level II and undergo radiotherapy and chemotherapy as in level III.
Level V: Patients receive the maximum tolerated dose (MTD) of gefitinib, radiotherapy 5 days a week for 6 weeks, and chemotherapy as in level III.
Patients with clinical or radiologic evidence of residual disease are required to undergo neck dissection approximately 8 weeks after completion of radiotherapy or chemoradiotherapy.
Patients resume oral gefitinib daily beginning 8 weeks after the completion of radiotherapy or chemoradiotherapy (12 weeks for patients who undergo neck dissection) and continuing for 2 years in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients are enrolled sequentially beginning at level I until the MTD of gefitinib is determined. The MTD is the dose preceding that at which at least 2 of 6 patients experience dose-limiting toxicity.
Twelve additional patients receive the MTD of gefitinib in combination with radiotherapy with or without cisplatin.
Patients are followed every 6 months for at least 5 years.
PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00033449
|United States, Colorado|
|University of Colorado|
|Denver, Colorado, United States, 80217-3364|
|Principal Investigator:||David Raben||University of Colorado, Denver|